Semiquantitative analysis of Th1 and Th2 cytokine expression in CD3+, CD4+, and CD8+ renal-cell-carcinoma-infiltrating lymphocytes

被引:12
作者
Elsässer-Beile, U
Grussenmeyer, T
Gierschner, D
Schmoll, B
Schultze-Seemann, W
Wetterauer, R
Mönting, JS
机构
[1] Univ Freiburg, Dept Urol, Expt Res Grp, D-79106 Freiburg, Germany
[2] Univ Freiburg, Inst Med Biometry, D-79106 Freiburg, Germany
关键词
renal cell carcinoma; TIL; cytokine expression;
D O I
10.1007/s002620050566
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The mRNA expression of Th1 and Th2 cytokines was compared in freshly isolated CD3(+) tumor-infiltrating lymphocytes (CD3(+) TIL) and in autologous CD3(+) peripheral blood lymphocytes (CD3(+) PBL) obtained simultaneously from 20 patients with renal cell carcinomas (RCC). In addition cytokine expression was compared in CD4(+) TIL and CD8(+) TIL from another group of 20 patients with RCC. TIL were isolated from mechanically disaggregated tumor material and PBL from peripheral blood by gradient centrifugation and subsequent selection with anti-CD3, anti-CD4 or anti-CD8 magnetic beads. In these pure lymphocyte preparations the constitutive expression of interleukin-l (IL-1), IL-2, IL-10, interferon gamma (IFN gamma), and tumor necrosis factor alpha (TNF alpha) was determined by using a polymerase-chain-reaction-assisted mRNA amplification assay. In the CD3(+) TIL, levels of mRNA for IFN gamma, IL-10, IL-1 and TNF alpha were significantly higher than in the autologous CD3(+) PBL whereas IL-2 expression was rather low and did not differ in the two populations. Comparison of cytokine mRNA expression in CD4(+) TIL and simultaneously obtained CD8(+) TIL revealed a significantly higher expression of IFN gamma in CD8(+) cells. These data reflect an in vivo activation of RCC-infiltrating lymphocytes at the mRNA level with respect to the Th1 as well as the Th2 immune response. Th1 activation seems to be most evident in the CD8(+) TIL.
引用
收藏
页码:204 / 208
页数:5
相关论文
共 32 条
[1]  
ALEXANDER JP, 1993, CANCER RES, V53, P1380
[2]  
Angevin E, 1997, INT J CANCER, V72, P431, DOI 10.1002/(SICI)1097-0215(19970729)72:3<431::AID-IJC10>3.3.CO
[3]  
2-3
[4]  
Asselin-Paturel C, 1998, INT J CANCER, V77, P7, DOI 10.1002/(SICI)1097-0215(19980703)77:1<7::AID-IJC2>3.0.CO
[5]  
2-Y
[6]  
BELLDEGRUN A, 1989, J IMMUNOL, V142, P4520
[7]  
BELLDEGRUN A, 1988, CANCER RES, V48, P206
[8]  
Brouwenstijn N, 1996, INT J CANCER, V68, P177, DOI 10.1002/(SICI)1097-0215(19961009)68:2<177::AID-IJC6>3.0.CO
[9]  
2-V
[10]  
BUKOWSKI RM, 1991, CANCER RES, V51, P4199